Summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Official Title
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Keywords
Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma, Multiple Myeloma, BMS-986393, Chimeric Antigen Receptor T-cell (CAR T-cell), CAR T-cell Therapy, Arlocabtagene Autoleucel, Arlo-cel, Recurrence, Cyclophosphamide, fludarabine, daratumumab, pomalidomide, Dexamethasone, carfilzomib